Use of amphotericin B with azole antifungal drugs: what are we doing?
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Since the 1950s, the standard agent prescribed for systemic antifungal therapy has been amphotericin B (36). Its broad spectrumofactivitymakesitanattractiveagentfortheempiric treatment of patients who may be infected with yeasts or molds.Itstrackrecordastheprimarytherapyformostinvasive mycosesiswellestablished,anditisstillwidelyregardedasthe agent of choice for the treatment of many patients with invasive mycoses. However, the toxicity of amphotericin B is well appreciatedandisoftenresponsibleforlimitingtheamountof drugthatcanbeadministered.Giventheimportanceofserious mycoses in clinical medicine and the need for alternative therapies for use in patients with fungal infections, research designed to identify new antifungal drugs has accelerated. The azole antifungal drugs are one example of the fruits of these efforts. Ketoconazole, fluconazole, and itraconazole have extended the ability to treat a variety of fungal infections with oral regimens (9, 11), without the toxicity of amphotericin B. One of the questions that has arisen following increasing experience with the azoles is whether they can be combined with amphotericin B to achieve synergy, to broaden their combined spectrum of activity, or to lower the dose of amphotericin B. Certainly, the availability of different antifungal drugs makes the administration of combinations of drugs not only possible but even desirable. Thus, combinations of amphotericin B with flucytosine have been suggested to be as effective andlesstoxicthanamphotericinBusedalone,especiallyinthe treatment of cryptococcal meningitis (6). Because ketoconazolecouldonlybegivenorallyanditsspectrumofactivitywas rather narrow, the use of combinations of amphotericin B with ketoconazolewerenotcommonlyencounteredinclinicalmedicine. Furthermore, studies by Schaffner and Frick (29) suggested that this combination might be antagonistic when used to treat aspergillosis. This observation supported the theoretical concerns that combinations of polyene antifungal drugs, which bind to ergosterol in the fungal cell membrane, and azoles, which inhibit the synthesis of ergosterol, would be antagonistic, irrespective of the fungal infection. Thus, with the
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rex, J. H., Bennett, J. E., Sugar, A. M., Pappas, P. G., van der Horst, C. M., Edwards, J. E., Washburn, R. G., Scheld, W. M., Karchmer, A. W., Dine, A. P., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411173312001 · Cited by 1,039
Self-citationAntifungal susceptibility testing
Rex, J. H., Pfaller, M. A., Rinaldi, M. G., Polak, A., & Galgiani, J. N. (1993) · Clinical Microbiology Reviews · doi:10.1128/cmr.6.4.367 · Cited by 361
Sangeorzan, J. A., Bradley, S. F., He, X., Zarins, L. T., Ridenour, G. L., Tiballi, R. N., & Kauffman, C. A. (1994) · The American Journal of Medicine · doi:10.1016/0002-9343(94)90300-x · Cited by 322
Redding, S., Smith, J., Farinacci, G., Rinaldi, M., Fothergill, A., Rhine-Chalberg, J., & Pfaller, M. (1994) · Clinical Infectious Diseases · doi:10.1093/clinids/18.2.240 · Cited by 269 · cited 1×
“resistance of Candida species recovered from patients with AIDS has been evaluated with in vitro correlations (8, 22, 27, 41, 45), and it appears that as the MICs increase, the rate of clinical failure also increases.”
Method
Cited by
Clinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug Resistance
White, T. C., Marr, K. A., & Bowden, R. A. (1998) · Clinical Microbiology Reviews · doi:10.1128/cmr.11.2.382 · Cited by 1,353
Current and emerging azole antifungal agents
Sheehan, D. J., Hitchcock, C. A., & Sibley, C. M. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.1.40 · Cited by 1,137
Rex, J. H., Pfaller, M. A., Galgiani, J. N., Bartlett, M. S., Espinel-Ingroff, A., Ghannoum, M. A., Lancaster, M., Odds, F. C., Rinaldi, M. G., Walsh, T. J., et al. (1997) · Clinical Infectious Diseases · doi:10.1093/clinids/24.2.235 · Cited by 855
“, although not consistently borne out by studies in vivo, depletion of cell-membrane ergosterol by prior azole therapy has the theoretical potential to reduce the efficacy of amphotericin B [51]).”
BackgroundLimper, A. H., Knox, K. S., Sarosi, G. A., Ampel, N. M., Bennett, J. E., Catanzaro, A., Davies, S. F., Dismukes, W. E., Hage, C. A., Marr, K. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2008-740st · Cited by 612
Galgiani, J. N., Ampel, N. M., Blair, J. E., Catanzaro, A., Johnson, R. H., Stevens, D. A., & Williams, P. L. (2005) · Clinical Infectious Diseases · doi:10.1086/496991 · Cited by 603
Metadata
- Authors
- Sugar, A. M.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 1995-09
- Volume
- 39
- Issue
- 9
- Pages
- 1907-1912
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2103659147
- Cited by
- 133
- References
- 4
- FWCI
- 7.28
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Use of amphotericin B with azole antifungal drugs: what are we doing? https://app.cochat.ai/papers/10.1128/aac.39.9.1907
- The paper
- Sugar, A. M. (1995). Use of amphotericin B with azole antifungal drugs: what are we doing? Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.39.9.1907
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.